Aroa Biosurgery Ltd
ARX
Company Profile
Business description
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Contact
64 Richard Pearse Drive
Mangere, Airport Oaks
Auckland2022
NZLT: +64 98693035
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2026
Employees
249
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
Our view after latest earnings report.
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.20 | 75.80 | -0.83% |
| CAC 40 | 8,013.67 | 96.12 | -1.19% |
| DAX 40 | 23,785.10 | 347.31 | -1.44% |
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% |
| FTSE 100 | 9,622.79 | 78.58 | -0.81% |
| HKSE | 25,952.40 | 205.96 | -0.79% |
| NASDAQ | 23,834.72 | 109.77 | 0.46% |
| Nikkei 225 | 51,497.20 | 914.14 | -1.74% |
| NZX 50 Index | 13,605.96 | 49.66 | 0.37% |
| S&P 500 | 6,851.97 | 11.77 | 0.17% |
| S&P/ASX 200 | 8,813.70 | 69.00 | -0.78% |
| SSE Composite Index | 3,960.19 | 16.33 | -0.41% |